title: Anticholinergics boost the pathological process of neurodegeneration with increased inflammation in a tauopathy mouse model.
abstract: Anticholinergics, and drugs with anticholinergic properties, are widely and frequently prescribed, especially to the elderly. It is well known that these drugs decrease cognitive function and increase the risk of dementia. Although the mechanism of anticholinergic drug-induced cognitive impairment has been assumed to be functionally reduced acetylcholine (ACh) neurotransmission, some data have indicated that anticholinergics might enhance the pathology of Alzheimer's disease. In this study, we investigated the pathological effects of anticholinergics on neurodegeneration. We chronically administered two anticholinergics, trihexyphenidyl (TP) and propiverine (PP) (the latter with less central anticholinergic action), to neurodegenerative tauopathy model mice 2 to 10 months old. Furthermore, because the ACh nervous system regulates both central and peripheral inflammation, we administered TP or PP to PS19 mice in which we had artificially induced inflammation by lipopolysaccharide injection. Tau pathology, synaptic loss, and neurodegeneration in the hippocampal region, as well as tau insolubility and phosphorylation, were markedly increased in TP-treated mice and mildly increased in PP-treated mice. Furthermore, immunohistochemical analysis revealed microglial proliferation and activation. Moreover, anticholinergics increased interleukin-1β expression in both the spleen and brain of the tauopathy model mice intraperitoneally injected with lipopolysaccharide to induce systemic inflammation. Interestingly, these alterations were more strongly observed in TP-treated mice than in PP-treated mice, consistent with the level of central anticholinergic action. Anticholinergic drugs not only impair cognitive function by decreased ACh neurotransmission, but also accelerate neurodegeneration by suppressing an ACh-dependent anti-inflammatory system. Anticholinergics should be less readily prescribed to reduce the risk of dementia.
authors: Laboratory for Neurodegenerative Disease Research, Clinical Research Center, Chiba East National Hospital, Japan. neuroyy@cehpnet.com
authors: Yasumasa
authors: Y
authors: Yoshiyama
authors: Ayako
authors: A
authors: Kojima
authors: Kimiko
authors: K
authors: Itoh
authors: Tomoyuki
authors: T
authors: Uchiyama
authors: Kimihito
authors: K
authors: Arai
mesh_terms: D000818:Animals; D001561:Benzilates / Q000494:pharmacology*; D018680:Cholinergic Antagonists / Q000494:pharmacology*; D004195:Disease Models, Animal; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007249:Inflammation / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D051379:Mice; D009410:Nerve Degeneration / Q000378:metabolism / Q000473:pathology*; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D024801:Tauopathies / Q000378:metabolism / Q000473:pathology*; D014282:Trihexyphenidyl / Q000494:pharmacology*; D016875:tau Proteins / Q000378:metabolism
chemical_list: D001561:Benzilates; D018680:Cholinergic Antagonists; D016875:tau Proteins; C015586:propiverine; D014282:Trihexyphenidyl